Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $448.3 million.

  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity fell 26.47% to $448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 20.51%. This contributed to the annual value of $576.8 million for FY2024, which is 60.11% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Liabilities and Shareholders Equity of $448.3 million as of Q3 2025, which was down 8.91% from $492.1 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $609.7 million during Q3 2024, with a 5-year trough of $328.2 million in Q1 2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $446.9 million, with a median of $403.9 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 30.63% in 2023, then spiked by 61.57% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Liabilities and Shareholders Equity stood at $444.3 million in 2022, then fell by 18.92% to $360.2 million in 2023, then spiked by 60.11% to $576.8 million in 2024, then dropped by 26.47% to $448.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $448.3 million in Q3 2025, compared to $492.1 million in Q2 2025 and $527.8 million in Q1 2025.